1. Home
  2. NUVL vs AMG Comparison

NUVL vs AMG Comparison

Compare NUVL & AMG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuvalent Inc.

NUVL

Nuvalent Inc.

HOLD

Current Price

$109.56

Market Cap

7.1B

Sector

Health Care

ML Signal

HOLD

Logo Affiliated Managers Group Inc.

AMG

Affiliated Managers Group Inc.

HOLD

Current Price

$271.88

Market Cap

7.6B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
NUVL
AMG
Founded
2017
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
7.1B
7.6B
IPO Year
2021
1997

Fundamental Metrics

Financial Performance
Metric
NUVL
AMG
Price
$109.56
$271.88
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
14
5
Target Price
$134.29
$275.00
AVG Volume (30 Days)
756.3K
278.7K
Earning Date
10-30-2025
11-03-2025
Dividend Yield
N/A
0.01%
EPS Growth
N/A
6.83
EPS
N/A
16.71
Revenue
N/A
$2,042,100,000.00
Revenue This Year
N/A
$3.58
Revenue Next Year
N/A
$12.63
P/E Ratio
N/A
$16.35
Revenue Growth
N/A
1.13
52 Week Low
$55.54
$139.22
52 Week High
$112.88
$276.40

Technical Indicators

Market Signals
Indicator
NUVL
AMG
Relative Strength Index (RSI) 62.75 69.11
Support Level $103.51 $264.01
Resistance Level $112.11 $276.40
Average True Range (ATR) 5.16 7.30
MACD -0.24 0.71
Stochastic Oscillator 83.81 88.08

Price Performance

Historical Comparison
NUVL
AMG

About NUVL Nuvalent Inc.

Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

About AMG Affiliated Managers Group Inc.

Affiliated Managers Group offers investment strategies to investors through its network of affiliates. The firm typically buys a majority interest in small to mid-size boutique asset managers, receiving a fixed percentage of revenue from these firms in return. Affiliates operate independently, with AMG providing strategic, operational, and technology support, as well as global distribution. At the end of June 2025, AMG's affiliate network—which includes firms like Abacus Capital and Pantheon dedicated to private markets (which accounted for 19% of AUM), AQR Capital and Capula Investment Management in liquid alternatives (24%), and Harding Loevner, Tweedy Browne, Parnassus, and Yacktman in equities, multi-asset, and bond strategies (57%)—had $771 billion in managed assets.

Share on Social Networks: